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ABSTRACT 
The overall aim of this work was to find biomarkers for Alzheimer’s disease 
(AD) in such an easily accessible body fluid as blood and investigate the implications 
of these biomarkers for the AD mechanism. The central and most studied 
histopathological features in AD brain are the amyloid plaques. Even at the preclinical 
stage of AD, amyloid beta (Aβ) peptides already start to form plagues. It still remains 
unclear whether Aβ oligomers and fibrils initiate the molecular cascade that ultimately 
leads to AD. So far, all Aβ-centered therapy approaches have had little success. 
Therefore, a fresh, unorthodox look at the AD initiation and biomarkers of the disease 
development is required.  
Since the primary risk factor for AD is age, biomarkers of protein aging could 
hypothetically be linked to AD. One of the main protein aging pathways is isoaspartate 
(isoAsp) accumulation; increased isoAsp levels are found in AD amyloid plaques. Thus 
we developed a mass spectrometry-based platform and workflow for isoAsp detection 
and quantification (Paper I), and applied them for the analysis of blood plasma samples 
from AD patients and healthy controls. We found increased levels of isoAsp in all 
stages of dementia (Paper II), which supported the hypothetical mechanism in which 
isoAsp accumulation triggers a sequence of events resulting in AD. To further 
investigate the impact of isoAsp accumulation in the central nervous system, we 
analyzed the brains of the transgenic mouse model lacking isoAsp repair via 
methylation (Paper III), and found that, along with the increased isoAsp levels, 
glutamate pathway is seriously distorted. IsoAsp can be cleared from the organism, 
besides repair, by means of proteases. When analyzing protein abundances in blood, we 
found links between these protein functions and AD development (Paper IV). The 
changes in the protein abundances were small, but nevertheless predictive of the AD 
progression. How early can one detect the imminent AD development by protein 
biomarkers? To address this question in the best possible scenario (a well-controlled 
system, brain biopsy), we analyzed the brain proteome of young transgenic mice and 
found statistically significant changes occurring long before the onset of AD-like 
symptoms (Paper V). Therefore, protein abundances, together with isoAsp levels, are 
promising biomarker candidates for AD diagnostics and prognostics, and mass 
spectrometry is an adequate tool for analyzing them. 
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Necl 1 nectin-like molecule 1  
NFTs neurofibrillary tangles 
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PCA principal component analysis 
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S-MCI stable mild cognitive impairment 
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1 INTRODUCTION 
1.1 ALZHEIMER’S DISEASE 
1.1.1 Background 
Alzheimer’s disease (AD) is a severe neurodegenerative disease and the main 
cause of dementia. There are more than 35 million dementia patients worldwide, and 
the number is estimated to reach 115 million by the year 2050.1 AD gradually affects 
the cognitive and everyday executive abilities of the patients, with advanced ones 
requiring help with the basic activities of daily living and ultimately dying of the 
disease.2 It is estimated that the initiation of AD begins 10-15 years before the clinical 
onset, and the clinical progression rates differ among AD patients.3 In the clinics, the 
diagnosis of AD relies on medical history, physical and neurological examination, as 
well as structural and functional brain imaging techniques. According to Alzheimer's 
Association, the AD experts can diagnose the disease with more than 90% accuracy. 
Currently, the definite diagnosis can only be achieved in postmortem brain 
examination, while the new AD definition proposed by the International Working 
Group, which allows accurate in vivo diagnosis of AD, remains to be commonly 
adopted by the clinical community.4 Currently there is no treatment to prevent or cure 
AD, which might be partially due to the lack of early and accurate clinical diagnosis.3 
To address these issues, in the year 2011 the National Institute on Aging defined three 
stages of AD: dementia due to AD; mild cognitive impairment (MCI) due to AD; and 
preclinical AD, and recommended implementing biomarkers as a complementary 
diagnosis tool.5 MCI is the stage where patients experience more memorial impairment 
compared with healthy controls while less cognitive impairment compared with mild 
AD patients.6 On average, the risk of these MCI patients progressing into AD increases 
10-12% every year, which is faster compared with healthy subjects. However, not 
every MCI patient will develop AD.6 It remains challenging to predict the clinical 
outcome for the MCI patients. 
 
1.1.2 The amyloid cascade hypothesis 
The molecular pathognomonic hallmarks of AD brain include the deposition of 
extracellular amyloid plaques composed of amyloid beta (Aβ) peptides and the 
formation of intracellular neurofibrillary tangles (NFTs) composed of hyper-
phosphorylated tau proteins. Although the molecular linkage between Aβ accumulation 
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and tau pathology remains unclear, it is generally accepted that tau pathology is 
downstream of  Aβ accumulation in AD progression.7, 8 Amyloid cascade hypothesis, 
which suggests that the imbalance between Aβ production and clearance causes the 
aggregation of Aβ peptides, and thus triggers the process of neurodegeneration, 
proposes Aβ accumulation as the primary event in AD pathogenesis.8 There are many 
experimental observations that support this hypothesis, e.g. the fact that the genetic 
mutations that perturb Aβ metabolism can lead to early onset of AD, with the upstream 
Aβ oligomers being more neurotoxic than the plagues themselves.8 But there are also 
observations that cannot be explained by the hypothesis, such as the poor correlation 
between the brain amyloid loads and the degree of patients’ cognitive impairment. 
Moreover, many healthy subjects have substantial amyloid deposits in their brains.9, 10 
There are many forms of Aβ peptides found in AD brains, but it still remains unclear 
which isoform(s) of Aβ initiate(s) the formation of the neurotoxic soluble Aβ 
oligomers.11 The N-terminal truncated form with pyroglutamate at the third position, 
AβpE3-42, has more than 2-fold and up to 250-fold higher propensity to form oligomers 
than Aβ40 and Aβ42 under several different conditions in vitro.12, 13 Thus it is possible 
that AβpE3-42 forms oligomers earlier than other Aβ peptides in vivo.  
To investigate the role of Aβ, many transgenic mouse models have been 
developed, however, none of them can fully cover the comprehensive neuropathology 
of human AD brain.14 For AD amyloid studies, there are several mouse strains 
established, e.g. PDAPP,15 Tg2576,16 J20,17 APP23,18 TgCRND8,19 and 5XFAD 
mice.20 While all of these mouse models form amyloid plaques, none show NFTs in the 
brain.14 These transgenic mice develop amyloid plaques at different time points with 
various amyloid forms (diffused or condensed), and many of them do not show 
significant neuron loss in the brain.14 Therefore, the animal models should be chosen 
according to the specific aims of the research.  
The TBA42 mouse model that exclusively expresses AβpE3-42 in the brain exhibits 
neurodegeneration without any apparent plagues and tangles, which confirms the 
neurotoxicity of soluble AβpE3-42.21 Crossing this transgenic mouse model with a 
conventional AD model 5XFAD results in the increased amyloid loads in their 
offspring, which supports the “seeding” role of AβpE3-42.22 Thus the TBA42 mice may 
serve as a well-established model to investigate the early molecular events in AD. 
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1.1.3 Biomarkers of Alzheimer’s disease 
Although amyloid cascade is the central and most studied topic in AD research, 
there is little success in developing the Aβ-centered therapeutics.8 As the preclinical 
stage of AD lasts more than one decade, the medical intervention timing is crucial. 
Currently AD cannot be confirmed by any single test, and the patients are mostly 
diagnosed at the late stage of the disease. Therefore AD biomarkers for early diagnosis 
and prognosis are of demand. 
The ideal biomarkers should be reliable, non-invasive, and inexpensive. So far 
the most studied and validated biomarker candidates are the polypeptides in the 
cerebrospinal fluid (CSF). (The imaging biomarkers are also strong and promising 
candidates,23 while they are out of the scope of this thesis.) Aβ42, total tau, and 
phosphorylated tau are in use for discriminating AD versus healthy subjects with the 
sensitivity and specificity around 80-90%.24 For predicting the clinical development of 
MCI patients, whether they will progress to AD (P-MCI) or remain stable as MCI (S-
MCI), CSF biomarkers could achieve sensitivity and specificity around 80%,25 
although broader validation might be needed.26, 27 However, obtaining CSF is invasive 
and CSF is not routinely analyzed for MCI patients in most of the countries. 
Compared with CSF, obtaining blood is much less invasive and blood samples 
are routinely analyzed in the clinics. A number of studies has investigated blood 
samples in search for AD biomarkers in the past decade.27 One of such studies 
identified a panel of 18 signaling plasma proteins that can differentiate AD versus 
healthy subjects with the sensitivity and specificity around 90%.28 In this study, the 
combination of those 18 proteins could discriminate S-MCI and P-MCI with the 
sensitivity and specificity around 80%,28 which is the best result achieved among this 
type of studies to date.  
 
1.2 Isoaspartate 
1.2.1 The origin of isoaspartate 
Besides the amyloid hypothesis, there are other proposed disease mechanisms, 
including: the neurovascular hypothesis, the inflammatory mechanism, and the protein 
aging theory. These mechanisms are not necessarily mutually exclusive: for instance, 
protein aging hypothesis helps explaining what process initiates aggregation of 
polypeptides, including Aβ.29 One of the major protein aging pathways is the 
accumulation of isoaspartic acid residues (isoAsp) in protein sequences. 
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IsoAsp is generated from either asparagine residue (Asn) deamidation or aspartic 
acid residue (Asp) isomerization through the succinimide intermediate. Succinimide is 
labile to hydrolysis which process results in a mixture of Asp and isoAsp with a typical 
ratio around 1:3 (Figure 1).30 Both deamidation and isomerization are spontaneous 
reactions under physiological condition, and the reaction rate is influenced by protein 
primary sequence, protein structure, pH, temperature, and buffer ionic strength.31  
IsoAsp accumulates significantly with time in long-lived proteins, such as α-crystallin 
in eye lenses32 and even albumin33 in blood. However, the enzyme, protein L-
isoaspartyl methyltransferase (PIMT) initiates the conversion of isoAsp into 
succinimide using S-adenosylmethionion (AdoMet) as the methyl donor, which will 
partially hydrolyze into Asp residues. 
 
Figure 1. Asn deamidation and Asp isomerization reactions that generate isoAsp and Asp. 
 
1.2.2 Biological significance of isoaspartate 
Under physiological conditions, the isoAsp introduced site-specifically by 
deamidation and isomerization can have regulatory functions, such as promoting DNA 
damage-induced apoptosis34 and suppressing p53 activity.35 But mostly, the presence of 
isoAsp is damaging, as the rearrangement of CH2 group from the Asn/Asp side chain to 
the backbone can disrupt protein structure and affect its function. IsoAsp accumulation 
that occurs in the natural process of aging usually has negative impact, e.g. isoAsp 
affects the stability of human lens32 and can induce autoimmune response.36 The 
introduction of isoAsp could also cause the polypeptide to become resistant to protease 
degradation.37 Therefore, isoAsp formation and PIMT repair capability have essential 
roles in both cellular regulation and protein aging processes. In pharmaceutical 
   5 
industry, minimizing deamidation and isomerization during drug production, 
formulation and storage is of great importance.38 
To further explore the biological influence of isoAsp accumulation, transgenic 
mouse strain with the deletion of the gene encoding PIMT has been established.39, 40 
The deletion of PIMT gene causes isoAsp accumulation in all the tissues measured in 
the studies, especially in the brain.39, 40 These PIMT-knockout (KO) mice have 
perturbed synaptosome glutamate uptake and die prematurely of epileptic seizures.39 As 
the expression of PIMT is crucial for survival, the in vivo substrates of PIMT have been 
under intense studies.41-44 Because of the strong physiological response, there are 
reasons to suspect that the PIMT knockout affects important brain pathways.39, 40 So far, 
it has been reported that PIMT regulates p53 activity,35 and the absence of PIMT results 
in activation of the insulin45, 46 and MEK-ERK pathways.47 
 
1.3 Isoaspartate and AD – the protein aging hypothesis 
The protein aging hypothesis of AD reinforces the role of Aβ peptide by 
proposing that the cyclization of Asp in Aβ peptides initiates the aggregation that 
decades later results in the disease.48 In a broader perspective, it is the deterioration 
(deamidation and isomerization) of polypeptides, including Aβ peptides as well as 
other amyloidogenic proteins that triggers protein aggregation, and thus leads to other 
downstream molecular cascades.49 IsoAsp has been localized in Aβ peptides from 
amyloid plagues purified from AD brains at positions 1, 7 and 23.50, 51 Also, higher 
amount of isoAsp has been identified in Aβ peptides as well as paired helical filaments 
of AD brain compared with healthy subjects.52 However, the questions related to the 
identities of other proteins bearing isoAsp damages, and whether they are 
amyloidogenic, have been poorly investigated so far.53 
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2 AIMS OF STUDY 
The aims of this Ph.D. thesis were to search for protein biomarkers of AD in 
blood and, if these are found, investigate the implications of these biomarkers for the 
AD mechanism. More specifically, the aims included: 
 
1. to establish and optimize mass spectrometry-based platform and workflow for 
the study of isoAsp at the whole proteome level (Paper I); 
 
2. to analyze the correlation of human blood isoAsp levels with dementia and AD 
progression (Paper II); 
 
3. to further investigate the effects of isoAsp accumulation in the brain tissue of 
PIMT knockout transgenic mice (Paper III); 
 
4. to search for blood prognostic biomarkers for AD among polypeptide 
abundances (Paper IV); 
 
5. to probe the presence of early molecular signatures of AD in the 
presymptomatic AD mouse model (Paper V). 
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3 METHODOLOGY 
3.1 Biomarker discovery by mass spectrometry 
Mass spectrometry-based proteomics has been the driving force behind protein 
biomarker discoveries for the past decades. A modern mass spectrometer can routinely 
reach mass accuracy of 5 ppm at femtomole sensitivity, dynamic range of 3-4 orders of 
magnitude (up to six orders of magnitude in targeted analyses)54 and identify thousands 
of proteins in a couple of hours.55 However, it remains challenging to develop protein 
biomarkers in human blood, because of the large dynamic range (ten or eleven orders 
of magnitude), high complexity (more than 9,000 proteins) and wide interpersonal 
viabilities of blood proteome.56 As a result, it requires extensive fractionation to cover 
the majority of the blood proteome, or using enrichment or depletion methods to reduce 
the dynamic range and focusing only on a subset of the whole blood proteome.56 
The well-established protein biomarker discovery strategy is the “shotgun” 
proteomics, which profiles the proteome by analyzing the enzymatic digests of 
complex protein mixtures.57 The digests composed of polypeptides are then separated 
by the liquid chromatography (LC) system coupled with a mass spectrometer. Mass 
spectrometry (MS) records the mass over charge ratio (m/z) of the polypeptide ions and 
their abundance. Every molecule with an appropriate m/z signature (e.g. Trypsin-
digested peptides are typically doubly or multiply charged.) is selected for 
fragmentation by tandem mass spectrometry (MS/MS). The fragments contain 
sequence information, which is used for peptide/protein identification by database 
searching using search engine like Mascot, SEQUEST, or Andromeda. Both isotopic 
labeling (e.g. iTRAQ,58 TMT,59 and SILAC60) and label-free (e.g. spectral counting61 
and ion current integration62) quantification methods are used intensively in proteome 
quantification.63 However, for biomarker discovery and animal model studies, isotopic 
labeling can become prohibitively expensive and impractical,64 thus label-free protein 
quantification method was used throughout this thesis.62 The quantified proteome data 
can then be subsequently submitted to various statistical software and bioinformatics 
databases and tools (e.g. REACTOME, KEGG, and DAVID) for further biological 
interpretation.   
AD biomarker studies have mostly focused on proteins at low concentrations, 
e.g. cytokines, which cannot be easily accessed by MS-based methods. Thus the 
accuracy of the measured protein abundance suffers from low signal levels, which 
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reflects in the large (>>10%) coefficient of variability (CV).65 In contrast, abundant 
blood proteins can be measured by label-free analysis with CVs as low as 1%, by 
which method, a panel of 20 abundant blood proteins can differentiate males from 
females from a single LC/MS analysis with ca. 90% accuracy.62 Thus if AD 
progression perturbs the abundance of the top 100-200 abundant blood proteins (“top 
proteome”), one can hypothesize that a standard proteomic experiment that requires 
minimum sample preparation may suffice for AD prognosis with acceptable accuracy. 
Indeed, the third most abundant blood protein, α-2-macrogloblin (A2M), is viewed as 
one of the AD biomarker candidates.66, 67 Therefore we analyzed the “top proteome” in 
search for biomarkers throughout this thesis. 
 
3.2 Isoaspartate detection (Paper I) 
Asp and isoAsp are structural isomers with identical molecular composition and 
similar physiochemical properties, and therefore it is quite challenging to distinguish 
the two by LC-MS. Several isoAsp detection methods have been developed, including 
Edman sequencing,68 the ISOQUANT Isoaspartate Detection Kit (Promega) utilizing 
the enzyme activity of PIMT,69 isoAsp specific antibodies,70 endoproteinase Asp-N 
based method,71, 72 affinity enrichment method,73 isotopic 18O labeling method,74 and 
high performance liquid chromatography (HPLC) method.75 MS/MS has also been 
explored for isoAsp identification. Collisional activated dissociation (CAD) was found 
to generate lower b/y ion ratio, less abundant b-H2O, y-46 as well as Asp immonium 
fragment ions at the isoAsp site, but these findings were found to be sequence-
dependent.76, 77 Synthetic peptides have been investigated in the negative ion mode in 
electrospray MS as well as in the positive ion mode with higher-energy C-trap 
dissociation (HCD), but no specific signature for isoAsp has been found.78, 79 In 
electron capture dissociation and electron transfer dissociation (ETD/ECD), the 
presence of isoAsp produces signature fragments of c•+58 and z’-57 ions (Figure 2).80  
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Figure 2. Left: ETD fragmentation pattern of a polypeptide containing Asp or isoAsp. The z’-
57 and/or c•+58 fragments indicate the presence of isoAsp. Right: ECD MS/MS spectra of 
peptide LDLAGR 2+ molecular ions. 
 
The main challenge for applying this method to analyze the biological complex 
mixtures is the fact that the peptides containing isoAsp are of low abundance. Therefore 
the signature fragments that are of even lower intensity can be drowned in noise. 
Sometimes the signature fragments overlap with isotopic distributions of other ions, 
which further complicate the detection of isoAsp. High resolution MS/MS can greatly 
help alleviate these problems. 
In order to develop a suitable platform for proteome-wide isoAsp identification, 
we analyzed 32 human proteome samples by HPLC coupled with a 7 Tesla linear trap 
quadrupole (LTQ) Fourier transform mass spectrometer (Thermo Fisher Scientific). 
Each of the trypsin digested peptides that gave ions with z≥2 was fragmented by CAD 
as well as ECD. To test the specificity of isoAsp detection using the accurate mass of 
the signature fragments, high resolution was employed not only for peptide masses, but 
also for the detection of MS/MS fragments. From these samples, 466 isoAsp peptide 
candidates were identified based on the accurate mass of the signature fragments alone. 
However, many of the signature fragments from these isoAsp peptide candidates were 
found coming from spurious noise, overlapping with other fragment ions, or co-isolated 
ions in MS/MS spectra. Therefore, additional criteria were required to validate these 
candidates. These criteria include: complex chromatographic peak shape, presence of 
adjacent c and z fragments, high mass accuracy of 5 ppm, absence of specific Asp loss 
from the charge-reduced species, presence of the isotopic peaks of the signature 
 10 
fragments, less abundant CO2 loss from c, z fragments, presence of complementary 
specific fragments, and the same signature fragments found in multiple spectra.  
Upon filtering with the above criteria, 219 isoAsp peptides have been confirmed 
by at least one criterion. Among these isoAsp peptides, 11 cases (five resulting from 
deamidation and six from isomerization) have been found as exceptionally convincing. 
Among the identified proteins, heat shock cognate, pyruvate kinase and actin have been 
identified earlier as substrates for PIMT.81  
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4 RESULTS AND DISCUSSION 
4.1 Blood isoAsp accumulation in dementia patients (Paper II) 
As mentioned, increased levels of isoAsp have been found in AD brain compared 
with healthy subjects,52 and isoAsp has been detected in Aβ peptides from amyloid 
plagues.50, 51 However, the role of other proteins bearing isoAsp damages in AD has not 
been explored. As increased levels of isoAsp have been found in blood samples of 
uremia patients who share some common pathology with AD patients,33 we 
hypothesized that AD patients may also have higher level of isoAsp in their blood 
samples. Moreover, as females have higher prevalence for AD,82 higher level of isoAsp 
in female blood should be expected compared to male blood. 
To improve the detection sensitivity, we modified our previous proteome-wide 
isoAsp detection method (Paper I) by acquiring the ETD MS/MS spectra in the Velos 
linear ion trap. This resulted in fragmentation of many more peptides, but the benefits 
of high resolution detection of MS/MS fragments were lost. Therefore, two additional 
criteria were implemented to filter out erroneous isoAsp identifications. The criteria 
were: Mascot score >25, and the absence of mass overlap of the isoAsp signature 
fragments with any c or z type fragments. Moreover, to eliminate the artifact brought 
up by in vitro Asn deamidation, we focused on isoAsp originating from Asp 
isomerization only. Because the rate of Asp isomerization is much slower compared 
with Asn deamidation,83 the majority of the detected isoAsp residues should originate 
in vivo. 
218 blood plasma samples were pooled into eight groups based on sex (male, 
female) and disease progression (healthy subjects, S-MCI, P-MCI, and AD). These 
pooled samples were digested with trypsin and analyzed by MS/MS with HCD and 
ETD. The overall abundance of isoAsp in each sample was quantified by spectral 
counting method. The number of isoAsp-containing peptide MS/MS spectra was 
normalized by the total number of MS/MS queries in each LC/MS run. From the 
pooled samples, we found that MCI and AD patients have significantly (p<0.05) higher 
number of isoAsp counts (>10%) compared with healthy subjects, so do females 
(>10%) compared with males (p<0.01).  
To validate the findings in the pooled samples, twelve individual, age-matched 
samples from each group were selected and analyzed in the same way as the pooled 
samples. The results for healthy subjects and dementia patients both from the pooled 
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and individual samples are shown in Figure 3A. The p-value for the isoAsp count 
differences between the dementia patients and healthy subjects was found by Fisher 
formula to be 0.01.84 Similar results were obtained from females compared with males 
(Figure 3B).  
Therefore, our hypothesis of both AD and sex effects on the isoAsp level in 
blood has been verified. The isoAsp-AD link is consistent with the previous findings 
for AD brains,52 although the exact mechanism connecting these two findings remains 
unclear. The increased level of isoAsp in dementia and female blood samples can be 
hypothetically linked to the lower ratio of AdoMet to S-adenosyl-L-homocysteine in 
blood,85-87 which potentially indicates lower repair efficiency by PIMT, assuming that 
its enzymatic activity exists in peripheral blood. 
 
Figure 3. Box plot for the isoAsp abundance (counts) detected in human blood plasma: A: 
healthy subjects versus dementia patients; B: female subjects versus male subjects. Adapted 
from 29, with permission from IOS Press. 
  
Although the excess of isoAsp counts in dementia patients is relatively low 
(around 15% on average), MS/MS spectral counts are logarithmically linked with 
peptide abundances,88 and therefore the isoAsp level differences are likely to be higher 
than 15%. Furthermore, a single isoAsp modification in a protein can significantly 
influence the aggregation rate of Aβ peptides interacting with this protein.50, 51 Thus 
isoAsp-containing protein species might play the “seeding” role in Aβ 
aggregation/amyloidogenesis in AD. And once the pathological processes are triggered, 
the blood isoAsp level becomes irrelevant (as long as it stays above the threshold), 
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which is consistent with our findings that the level of isoAsp does not scale with the 
severity of the disease. 
 
4.2 Effects of brain isoAsp accumulation (Paper III) 
To further explore the molecular effects of isoAsp accumulation, especially in the 
brain, we performed brain proteomic studies on a PIMT-KO transgenic mouse model. 
The deletion of the gene encoding PIMT in mice (Pcmt1) leads to significant isoAsp 
accumulation in the brain: the abundance of brain isoAsp in 30 to 40-day old PIMT-KO 
mice reaches six times higher levels compared to wild type (WT) mice, as measured by 
the ISOQUANT assay.39 Abnormalities of microtubule organization in the pyramidal 
neurons, together with proportional brain enlargement (around 15% increase) in 
cerebral cortex, hippocampus, striatum, thalamus, and cerebellum, have been observed 
in these PIMT-KO mice, while there was no significant change in the number of 
neurons or astrocytes.40 Finally these mice die prematurely of epileptic seizures.39  
Eight female mouse brain tissues (four Pcmt1-/- and four Pcmt1+/+) were 
analyzed in this study. We selected the in-solution filter-aided sample preparation 
(FASP) protocol that was not interfered by the large brain lipid contents.89 To 
corroborate the findings provided by FASP, we performed an additional proteomics 
analysis with gel electrophoresis. Although mass spectrometry was used for protein 
identification and quantification in both analyses, such a validation approach was still 
satisfactory due to the complementary nature of peptide sets detected with FASP 
compared with in-gel digestion.90 Moreover, this approach does not require 
significant changes of protein abundance (>50%) as required by the immunological 
validation methods. 
The same MS/MS settings as in Paper II were applied here for isoAsp 
detection. While in this study, higher levels of isoAsp were expected in the PIMT-KO 
mouse brain, which reduced the concern over in vitro deamidation. Therefore, isoAsp 
originated from both deamidation and isomerization was investigated. In total, 67 
unique isoAsp sites were identified. Four of the 12 isoAsp-containing proteins found 
by Vigneswara et al.,41 and nine of the 19 isoAsp-containing proteins found by Zhu et 
al.,81 were confirmed in our results. Moreover, we identified the specific sites of 
damage (isoAsp) in each of these proteins.  
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For isoAsp peptide quantification, reliable base-line chromatographic separation 
between the native and isoAsp peptides was required, which cannot always be 
achieved. Since the main goal was to assess the general isoAsp level in PIMT-KO and 
WT mouse brains, we selected two peptides as representatives with well-separated 
chromatographic peaks and reliable MS/MS identification of both native and isoAsp 
forms. The relative abundances of the variants were quantified by their extracted ion 
chromatogram. These two peptides are: 92VFDKDGNGYISAAEL107R from 
calmodulin and 65LVINGKPITIFQE78R from glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), both of which were deamidation products. Their isoAsp 
occupancies (isoAsp/native peptide ratios) are shown in Figure 4. The relatively large 
amount of isoAsp in the WT mouse proteins suggests that these Asn residues may be 
particularly labile and thus could have deamidated during sample preparation.  
 
Figure 4. IsoAsp occupancy: A: peptide VFDKDGNGYISAAELR from calmodulin; B: 
peptide LVINGKPITIFQER from GAPDH. Lines indicate the median value in each dataset. 
Reprinted with permission from 91. Copyright (2013) American Chemical Society. 
 
The peptide 92VFDKDGNGYISAAEL107R containing isoAsp-98 is located in the 
calcium binding loop of the calmodulin EF hand. Calmodulin contains four EF hand 
domains, all of which can bind calcium. Interestingly, the domain with Asn-98 has the 
highest calcium binding affinity among all domains.92 The transformation of Asn-98 to 
isoAsp-98 in calmodulin results in loss of 90% protein activity.93  
The domain which contains peptide 65LVINGKPITIFQE78R bearing isoAsp-68 
has no known catalytic activity of GAPDH, but it can bind tryptophanyl-tRNA 
synthetase,94 and contribute to membrane fusion.95 In vitro experiments have 
identified the N-terminal peptide (2VKVGVNGFG11R) as the main deamidation site 
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of GAPDH.96 To our knowledge, this is the first time that GAPDH has been 
identified as a potential in vivo substrate for PIMT. The biological effects of 
deamidation of Asn-68 in GAPDH are still unclear. The chromatographic profiles 
together with the ETD MS/MS spectra for the native and isoAsp peptide 
65LVINGKPITIFQE78R are given in Figure 5. 
 
Figure 5. Left: Extracted ion chromatographic profiles of 3+ ions of peptide 
65LVINGKPITIFQE78R (Asn) from GAPDH and its deamidated forms 
65LVIDGKPITIFQE78R (isoAsp) and 65LVIDGKPITIFQE78R (Asp) in the samples of A: 
PIMT-KO mice; B: WT mice. Right: ETD MS/MS spectrum of 3+ ions of C: the 
65LVIDGKPITIFQE78R (Asp) peptide; D: the 65LVIisoDGKPITIFQE78R (isoAsp) peptide. 
Insert shows the absence or presence of (z–57 Da) ions. Reprinted with permission from 91. 
Copyright (2013) American Chemical Society. 
 
At the proteome level, among the most reliable 151 significantly regulated 
proteins, 83 were found to be up-regulated in PIMT-KO mice, and 68 down-regulated. 
Using all identified proteins as the background dataset and p < 0.001 as a significance 
threshold, Gene Ontology analysis yielded cellular amino acid biosynthesis as the only 
significantly enriched process. Moreover, the abundances of enzymes involved in the 
glutamate-glutamine cycle were altered towards the accumulation of glutamate,39 
which is consistent with the previous observations of 30% more glutamate in 
synaptosomes of PIMT-KO mice.39 Excessive glutamate excitatory signals have been 
associated with epilepsy,97 thus the dysregulated glutamate-glutamine cycle may 
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account for the epileptic seizures and, subsequently, of untimely death of PIMT-KO 
mice. 
From our study, we confirmed that besides protein repair, PIMT has other 
regulatory effects, like in amino acid synthesis and glutamate-glutamine cycle. For the 
purpose of understanding the specific effects of isoAsp accumulation in the brain 
tissue, it will be of importance to carry out further functional studies of the proteins 
bearing significantly higher level of isoAsp in PIMT-KO mice.  
 
4.3 AD blood prognostic polypeptide biomarkers (Paper IV) 
In search for blood biomarkers of AD, we focused on the abundance changes of 
blood polypeptide for predicting AD progression in MCI patients. Blood plasma 
samples from 119 MCI patients (76 with S-MCI and 43 with P-MCI) were analyzed in 
two replicates (independent digestions) by the LC-MS/MS method mentioned in Paper 
II. For technical reasons, these samples were randomly assigned to be analyzed by two 
different LC systems in four series of experiments with at least two weeks break 
between each other. These experimental settings complicated the data analysis process, 
yet the obtained data were more representative of the real-life clinical settings. Relative 
abundances of the polypeptides were quantified by the label-free approach.62 AD 
progression biomarkers were selected by multivariate analysis using SIMCA software 
(Version 13.0.0.0, Umetrics AB, Sweden) followed by cross-validation of the 
predictive model.  
In total, 125 proteins were successfully quantified in all four groups of analyses. 
Orthogonal partial least squares discriminant analysis (OPLS-DA) model built for the 
discrimination of S-MCI and P-MCI groups showed predictive accuracy of 79%, with 
60 proteins as the significant discrimination factors. In the negative control, where P-
MCI/S-MCI identifier was randomly assigned, no valid OPLS-DA model can be built 
(Q2 =-0.08). 
Sex differences in human blood proteome are well known.29, 62, 98, 99 For instance, 
the level of A2M in the blood is typically 15%-20% higher in adult females than in 
adult males.100 According to the literature, A2M is an AD biomarker candidate.66, 67 
The overexpression of A2M in AD brains was found in 1991 based on 
immunohistological method.101 Later, the 5´ splice-site deletion in exon 18 of A2M was 
genetically linked to AD with the same degree of certainty as the APOE-ε4 allele.102 A 
20% increase of A2M abundance in the blood has been found in AD patients compared 
with healthy subjects.66 In our analysis, A2M level in the blood increased in P-MCI 
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females, but decreased in P-MCI males (Figure 6A). This observation is even stronger 
in the pooled data, where the same individual samples were pooled according to their 
sexes and disease progression.29 In the pooled samples, A2M level in P-MCI females is 
higher than in S-MCI females by 13%, and in males the corresponding level is lower by 
12% (Figure 6B).62 This sex-specific correlation of A2M excluded it from the 
significant discrimination factors by the OPLS-DA model. But when an OPLS-DA 
model was built specifically for female patients, A2M was suggested as one of the 
strongest factors. Therefore, sex factor has to be assessed and evaluated for all the 
biomarker studies.  
 
Figure 6. Box plot for the A2M abundance quantified from human blood plasma: A: 
abundances from individual samples; B: abundances from pooled samples. 
 
Among the 60 significant discrimination factors, complement cascade was 
enriched from the P-MCI negatively-correlating proteins. The complement activation 
has been suggested as the mechanism for amyloid clearance and possibly served as 
biomarkers.103 The involvement of complements here may reflect the inflammation 
aspect of the AD pathology and the response to it from the human immune system. On 
the other hand, hemostasis process was found enriched in the P-MCI positively-
correlating proteins. This feature strongly supports the recently uncovered role of the 
hemostatic system and the clotting process in AD.104 
As mentioned before, the current standard for discriminating P-MCI versus S-
MCI by blood proteins exhibits the specificity and sensitivity around 80%.24 Here, 
based on a panel of abundant blood proteins, we can achieve an accuracy of 79% in 
predicting AD onset (P-MCI). Among all the putative biomarkers proteins, 
ceruloplasmin,105 complement factor I,104 fibrinogen,104 and plasma protease C1 
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inhibitor,106 have been reported as increased in AD blood samples compared with 
healthy subjects.  
This study is the first step to build a flexible and robust AD progression 
predictive tool that is based on blood biomarkers. All reliably detected and quantified 
proteins were used in building the AD model, which leaves space for future 
optimization and validation. For clinical application of these AD progression prediction 
models, further extensive validation is required.  
 
4.4 Proteome alterations of presymptomatic AD mice (Paper V) 
In the above study, the changes of the blood protein abundances were rather 
small, but still sufficient to predict AD progression at the stage of MCI. How early can 
the imminent AD be predicted by protein biomarkers then? To address this question, 
we performed the brain proteome studies of young TBA42 transgenic mice. As 
mentioned, the TBA42 mice expressing the “seeding” forms of Aβ, AβpE3-42, in the 
brain,22 is a well-established model to investigate the early molecular events in AD. We 
chose to investigate the early proteome changes in the brain of four-month old 
presymptomatic TBA42 female mice. The proteomic experimental settings were 
similar as in Paper III.  
As expected, the whole-brain proteome changes in the presymptomatic AD mice 
were small compared with the age-matched controls. Yet the main component in 
principal component analysis (PCA) of protein abundances separated the proteomes of 
WT and TBA42 mice rather well. This result confirms that the early signature of 
pathology is already present in brain of TBA42 mouse at four months of age, before the 
onset of detectable behavioral symptoms. Detailed studies found three proteins 
significantly upregulated in TBA42 mice: 
 Cadm3 47 kDa protein, also known as nectin-like molecule 1 (Necl 1), is 
specifically expressed in the neurons. It is a Ca2+ independent immunoglobulin-like 
cell-cell adhesion molecule.107 The connection between Necl 1 and AD has not been 
explored yet, and its importance for TBA42 neuropathology remains unclear. 
 Homer1 protein belongs to Homer protein family. Its homologous proteins Homer2 
and Homer3 interact with amyloid precursor protein and inhibit Aβ production, 
whereas Homer1 seems not.108 The up-regulation of Homer1 might be 
mechanistically related to the cognitive deficits that TBA42 mice develop at a later 
time point.109 
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 Inositol-trisphosphate 3-kinase A (InsP3KA) converts inositol-1,4,5-trisphosphate 
(InsP3) to inositol-1,3,4,5-tetrakisphosphate in hippocampal, cortical and cerebellar 
neurons. Thus it is an important regulator of InsP3 induced calcium signaling 
pathway.110 Calcium signaling is intensively involved in neuron physiology, and 
enhanced intracellular calcium levels have an essential role in AD.111 The increased 
InsP3KA levels in young TBA42 mice may function as to decrease the InsP3 level, 
thus restoring the calcium balance.  
To put the proteome results in the context of signaling pathways, quantitative 
pathway analysis was performed using pathway search engine with TRANSPATH 
database.112 Briefly, protein IDs are converted into gene IDs, and mapped on known 
signaling pathways from the TRANSPATH database.113 Then an upstream search along 
the pathway networks is performed, the regulatory molecules on the pathway 
intersections (so called key nodes) are scored according to their connectivity to the 
input proteins and abundances.113  
Among all the significantly upregulated key nodes in TBA42 mice, three nodes 
were localized in mTOR/p70S6K anti-apoptotic signaling pathway. The mammalian 
target of rapamycin (mTOR) plays a pivotal role in multiple fundamental biological 
processes. A variety of reports suggested that the mTOR pathway modulates Aβ-related 
synaptic dysfunction in AD.114 The relevance of mTOR/p70S6K pathway in AD has 
also been confirmed by studies with Tg2576 AD transgenic mice,115 primary neuron 
culture from R1.40 mice,116  and in the brains of 3xTg-AD mice.117 Our results of 
increased mTOR signaling in young TBA42 mice is corroborated by these previous 
findings and further suggest that this pathway may be involved in presymptomatic 
neurodegeneration. 
Our data confirm that AD-typical molecular pathways can be detected by whole-
brain shotgun proteomics in young presymptomatic mice long before the onset of 
behavioral changes. 
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5 CONCLUSIONS 
From the above studies, we have demonstrated: 
1) for the purpose of proteome-wide detection of isoAsp in biological complex 
mixtures, the presence of the isoAsp signature fragments in ECD/ETD spectra 
in combination with additional criteria (either form MS or LC) are efficient for 
isoAsp identification; 
2) higher levels of isoAsp have been detected in blood plasma samples of 
dementia patients compared with healthy subjects, and females compared with 
males; 
3) besides isoAsp repair, PIMT has other regulatory effects such as a role in amino 
acid synthesis and glutamate-glutamine cycle in the brain; 
4) based on the top proteome of around 120 blood protein abundances, the 
prediction accuracy for the progression of MCI patients to AD can reach 79 %; 
5) AD-related molecular pathways can be detected in young presymptomatic 
transgenic AD mice long before the onset of behavioral changes. 
   21 
6 FUTURE PERSPECTIVES 
The updated AD Diagnosis Guidelines from the National Institute on Aging have 
suggested implementing brain imaging and CSF biomarkers in 2011.118 These 
biomarkers have already reached (e.g. Florbetapir) or approached clinical application. 
However, due to their relatively high cost and invasive sampling procedures, blood 
biomarkers are not only highly desirable for prognosis, diagnosis, and disease 
onset/intervention monitoring, but also for population screening or multistage 
screening.119 Therefore, this thesis was dedicated to search for AD blood biomarker 
candidates.  
All the biomarker studies carried out in this thesis are in the discovery phase, 
which was based on unbiased detection of protein expression and posttranslational 
modification differences in blood samples of the patients with different degrees of 
dementia. Before clinical use, these results will require further validation through 
independent analytical systems: ideally, using other than MS method, and preferably on 
thousands of samples. Thus before extensive validation is finished, all these findings 
should be regarded as “biomarker candidates”.120 
Since blood reflects the metabolism alterations from all tissues, the detected 
blood proteome disturbances may result from pathological processes indirectly linked 
to AD brain pathology. Therefore, the biomarker candidates that are either brain-
specific or identified both in CSF and blood could be more promising as the final 
biomarkers. Since the definite AD diagnosis still relies on postmortem brain 
examination, all current biomarker studies based on clinical diagnosis are limited by the 
accuracy of that diagnosis. Furthermore, there are many sources of potential analytical 
variations between different laboratories and clinics resulting from the differences in 
sample collection, transportation, storage and handling before the analysis. Therefore, 
standardization is required for a multi-cohort validation study. Validation of predictive 
biomarkers (P-MCI) is especially challenging as it requires relatively long follow-ups 
to corroborate the current diagnosis.119 As for the preclinical AD biomarkers 
development, well-designed longitudinal studies are needed. One such study has 
recently been launched by our group in collaboration with other KI groups and 
supported by AstraZeneca. The results of the current thesis will serve a basis for 
analytical proteomics approaches in that study. 
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Besides the development of AD blood protein biomarkers, we have also 
identified elevated levels of protein damages caused by isoAsp accumulation in MCI 
and AD patients. We hypothesized that isoAsp-containing proteins may play the 
“seeding” role in amyloidogenesis in AD. Although elevated levels of isoAsp-
containing proteins have been found in AD brain, their identities remain unknown. 
Therefore further investigations into the AD brain isoaspartome will facilitate the 
understanding of the protein ageing theory of Alzheimer’s disease.      
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